The company said its board currently includes eight directors, seven of whom are independent. From October 2011 to December 2013, Heller has served as the company director.
Most recently, Heller was a trustee and senior vice president of business development at Bristol-Myers Squibb. Currently, she is a trustee of the Dana Farber Cancer Institute. Previously, she was executive vice president of business development at Exelixis Pharmaceuticals and head of strategic alliances at Novartis Pharmaceuticals.
Perrigo to acquire United States rights for Entocort from AstraZeneca
US FDA approves Boehringer Ingelheim's Pradaxa
Phase II clinical trial for potential treatment of androgenetic alopecia completed by Samumed
Life Sciences Partners collaborates on immuno-oncology with Bristol-Myers Squibb
Arsanis initiates first cohort in Phase one clinical trial of ASN100
Impax introduces generic Avodart (Dutasteride) Capsules, 0.5 mg
Mylan unveils generic FazaClo orally disintegrating tablets for treating schizophrenia